OPS-2071
/ Otsuka
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
April 03, 2025
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
(clinicaltrials.gov)
- P2 | N=87 | Completed | Sponsor: Otsuka Beijing Research Institute | Recruiting ➔ Completed
Trial completion • Gastrointestinal Disorder
November 01, 2023
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
(clinicaltrials.gov)
- P2 | N=80 | Recruiting | Sponsor: Otsuka Beijing Research Institute | Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Disorder
June 28, 2023
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Otsuka Beijing Research Institute
New P2 trial • Gastrointestinal Disorder
March 01, 2023
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects.
(PubMed, Biomedicines)
- "Many possible drugs of the future for CDI, with diverse mechanisms of action, are in development in the form of microbiota-modulating agents (e.g., ADS024, CP101, RBX2660, RBX7455, SYN-004, SER-109, VE303, DAV132, MET-2, and BB128), small molecules (e.g., ridinilazole, ibezapolstat, CRS3123, DNV3837, MGB-BP-3, alanyl-L-glutamine, and TNP-2198), antibodies (e.g., IM-01 and LMN-201), and non-toxic strains of CD (e.g., NTCD-M3). The development of some therapeutic agents (e.g., DS-2969b, OPS-2071, cadazolid, misoprostol, ramoplanin, KB109, LFF571, and Ramizol) stopped due to failed clinical trials or unknown reasons...The current pipeline of anti-CDI medications appears promising. However, it will be fascinating to see how many of the cited are successful in gaining approval from drug regulators such as the US FDA and becoming medicines for CDI and r-CDI."
Journal • Review • Developmental Disorders • Infectious Disease
September 20, 2022
In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.
(PubMed, J Antimicrob Chemother)
- "The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter."
Journal • Preclinical • Infectious Disease
March 16, 2022
Correction for Oka et al., "In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile".
(PubMed, Antimicrob Agents Chemother)
- No abstract available
Journal • Preclinical
September 01, 2021
Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease.
(PubMed, Dig Dis Sci)
- "Our results suggest that OPS-2071 had both immunosuppressive and antibacterial effects. This dual effect makes OPS-2071 a unique and promising candidate for IBD."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • CD4 • IL12A • TNFA
July 15, 2021
Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats.
(PubMed, Dig Dis Sci)
- "OPS-2071 is expected to be a new therapeutic option for IBD as a gut microbiota modulator by significantly increasing A. muciniphila occupancy."
Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
May 09, 2021
[VIRTUAL] In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, Against Clostridioides difficile
(WMF 2021)
- "OPS-2071 has the potential to become a new therapeutic option for treating C. difficile infection."
Preclinical • Infectious Disease
May 09, 2021
[VIRTUAL] In Vitro And In Vivo Antibacterial Activities Of A Novel Quinolone Compound, Ops-2071, Against Clostridioides Difficile
(WMF 2021)
- "There is no abstract associated with this presentation."
Preclinical
June 22, 2021
"OPS-2071 from Otsuka Pharmaceutical shows potent in vitro and in vivo activity against Clostridioides difficile #WorldMicrobeForum"
(@Cortellis)
Preclinical
January 27, 2021
In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, Against Clostridioides difficile.
(PubMed, Antimicrob Agents Chemother)
- "Furthermore, OPS-2071 showed significant in vivo efficacy at 0.0313 mg/kg/day (50% effective doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, respectively, in a hamster model of C. difficile infection. OPS-2071 has the potential to become a new therapeutic option for treating C. difficile infection."
Journal • Preclinical
June 18, 2020
Efficacy and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation
(clinicaltrials.gov)
- P2; N=3; Terminated; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; N=240 ➔ 3; Trial completion date: Feb 2021 ➔ Apr 2020; Recruiting ➔ Terminated; Trial primary completion date: Jan 2021 ➔ Apr 2020; Sponsor Decision
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease
January 28, 2020
OPS-2071 HEALS T CELL MEDIATED COLITIS, MURINE CROHN’S DISEASE MODEL, WITH ANTI-INFLAMMATORY AND ANTI-BACTERIAL ACTIVITY
(DDW 2020)
- "Two weeks following T cell transfer, OPS-2071, sulfasalazine, anti-IL12/23 p40 antibody were administered for 3 weeks, followed by assessment of efficacy evaluation by histological score and inflammatory index...At high OPS-2071 concentrations, these effects were comparable to prednisolone. The Minimum Inhibitory Concentration against IBD-related bacteria for: OPS-2071, ciprofloxacin, and metronidazole were 0.015 - 0.5, 0.25 - 8, and 0.03 - >128 mg/mL, respectively... OPS-2071 demonstrated significant therapeutic effect on colonic inflammation in the murine T cell-mediated colitis model, suppressed immune response in vitro, and showed in vitro activity against bacteria related to CD. From these in vitro results, it can be concluded that OPS-2071 has anti-inflammatory activity, independent of its antibacterial activity. The dual effects demonstrated by this novel agent, OPS-2071, provided a rationale for exploring the impact of this compound on human CD in clinical trials"
Preclinical • Crohn's disease • Gastroenterology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD44 • IL12A
1 to 14
Of
14
Go to page
1